



**Date:** May 19, 2022

**Subject:** EVFM1 Options - Expiration Pricing Consideration

EVFM1 (adjusted Evofem Biosciences, Inc. options) will be subject to special pricing consideration in expiration processing on May 20, 2022. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of EVFM1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

**EVFM1**

EVFM1 options are adjusted Evofem Biosciences, Inc. options, adjusted May 6, 2022 (see OCC Information Memo #50374). The deliverable of EVFM1 options is:

**NEW DELIVERABLE**

**PER CONTRACT:**

- 1) 6 Evofem Biosciences, Inc. (EVFM) Common Shares
- 2) Cash in lieu of approximately 0.6667 fractional EVFM Shares

As of May 19, 2022, the EVFM Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a EVFM1 price for use in expiration processing, OCC will use the following formula:

$$\text{EVFM1} = 0.066667 (\text{EVFM})$$

For example, if EVFM closes at 1.03, the EVFM1 price would be:

$$\text{EVFM1} = 0.066667 (1.03) = 0.07$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).